IL6 and pulmonary edema: Digoxin significantly reduced pulmonary edema in the therapeutic group (p = 0.02) and decreased TNF-α levels (p = 0.014), while robustly suppressing IL-6 and MDA in both prophylactic and therapeutic settings (each p < 0.001).